Background: Non-alcoholic steatohepatitis is acondition of which diabetic fatty liver accounts for a large proportion. Metformin (met) is one of the most commonly used drugs to treat Diabetes Mellitus (DM) type II. Empagliflozin (Empa) is a sodium -glucose co-transporter 2 inhibitors , which has recently been shown to improve the prognosis in high-risk cardiovascular patients. Aim of the study: this work aimed at exploring the possible prophylactic effect of empa alone and in combination with met on NASH induced experimentally by high fat diet in rats with DM type II. Material and methods: 36 Rats were divided into 5 groups after experimental inductuion of DM type II : Control normal group , Untreated NASH diabetic group (received a high fat diet for 12 weeks), Met pre-treated NASH diabetic group (treated with met 100 mg/kg/day orally for 12 weeks) , empa pre-treated NASH diabetic group (treated with empa 10 mg/kg/day orally for 12 weeks) and met and empa pre-treated diabetic group(treated with met100 mg/kg/day and empa 10 mg/kg/day orally for 12 weeks). Results: Met and empa produced reduction of liver enzymes , total cholesterol, triglycerides and LDL-c , fasting blood glucose , insulin level and insulin resistance index and significant elevation of HDL-c and serum adiponectin These results were supported by marked improvement of liver histopathology compared to non-treated NASH diabetic group, with the best results obtained by administration of met along with empa . Conclusion:It was found that met and /or empa affords hepatoprotective effects. |
